Compare GCBC & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCBC | DNA |
|---|---|---|
| Founded | 1889 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.0M | 458.6M |
| IPO Year | 1998 | 2020 |
| Metric | GCBC | DNA |
|---|---|---|
| Price | $35.59 | $7.84 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 18.9K | ★ 1.0M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | 31.69 | ★ 46.49 |
| EPS | ★ 2.41 | N/A |
| Revenue | $4,117,000.00 | ★ $170,155,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.98 | ★ N/A |
| Revenue Growth | ★ 11.06 | N/A |
| 52 Week Low | $21.25 | $5.37 |
| 52 Week High | $36.02 | $17.58 |
| Indicator | GCBC | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 62.97 | 49.32 |
| Support Level | $33.84 | $6.38 |
| Resistance Level | N/A | $7.70 |
| Average True Range (ATR) | 0.73 | 0.33 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 90.35 | 70.33 |
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.